All In MedTech

Device Trial Radar · NCT04101669

The RESET System Pivotal Clinical Trial (Protocol Revision K)

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". Randomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

264

Planned (sponsor's estimate)

Start

Sep 9, 2019

Primary completion

Dec 30, 2027

Study completion Sep 30, 2029

Sponsor

Lead sponsor
Morphic Medical Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Biostatistical Consulting, Inc.
First posted
Sep 24, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (RESET):1 (Sham).

Conditions

  • Diabetes type2
  • Obesity

Interventions

  • RESET LinerDevice

    The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.

  • ShamOther

    Patient receives upper endoscopy but no treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: 9 Months
  2. SAE RateTime frame: 9 months

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Banner Health

    Gilbert, Arizona · Recruiting

  • M3 Wake Research

    Tucson, Arizona · Recruiting

  • MedStar Health Research Institute

    Washington D.C., District of Columbia · Recruiting

24 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.